HK Centre for Medical Products Regulation will be set up by end of 2026

已複製連結

The Department of Health announced the timetable for establishing the Hong Kong Centre for Medical Products Regulation and the roadmap for implementing "primary evaluation". 

The Hong Kong Centre for Medical Products Regulation (CMPR) will be established by the end of 2026, and the Department of Health will implement "primary evaluation" for new drug registration in phases beginning next year, with full implementation by 2030. 

These developments mark a significant milestone in Hong Kong's transformation into an international health and medical innovation hub.   

The Director of Health, Dr Ronald Lam, said, "The Hong Kong Special Administrative Region Government is committed to raising regulatory standards for medical products in Hong Kong. With the establishment of the CMPR, we will consolidate regulatory functions for Western and Chinese medicines, as well as medical devices, and enhance the existing regulatory regime in a holistic manner. The vision of the CMPR is to become a "leading, internationally renowned medical products regulatory authority, driving excellence and innovation", with the goal of gaining international recognition in the field. "